![]() |
Name |
epi-Aszonalenin A
|
Molecular Formula | C25H25N3O3 | |
IUPAC Name* |
(2S,10S,12S)-3-acetyl-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.02,10.04,9.015,20]henicosa-4,6,8,15,17,19-hexaene-13,21-dione
|
|
SMILES |
CC(=O)N1[C@H]2[C@](C[C@@H]3N2C(=O)C4=CC=CC=C4NC3=O)(C5=CC=CC=C51)C(C)(C)C=C
|
|
InChI |
InChI=1S/C25H25N3O3/c1-5-24(3,4)25-14-20-21(30)26-18-12-8-6-10-16(18)22(31)28(20)23(25)27(15(2)29)19-13-9-7-11-17(19)25/h5-13,20,23H,1,14H2,2-4H3,(H,26,30)/t20-,23+,25-/m0/s1
|
|
InChIKey |
TXNJQKDZOVFCAQ-ZWSUVBHBSA-N
|
|
Synonyms |
epi-Aszonalenin A; 908853-14-5; (2S,10S,12S)-3-acetyl-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.02,10.04,9.015,20]henicosa-4,6,8,15,17,19-hexaene-13,21-dione; 5-acetyl-14a-(1,1-dimethyl-2-propen-1-yl)-5aS,13aS,14,14aS-tetrahydro-indolo[3',2':4,5]pyrrolo[2,1-c][1,4]benzodiazepine-7,13(5H,12H)-dione; HY-135154; CS-0109647
|
|
CAS | NA | |
PubChem CID | 102254364 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 415.5 | ALogp: | 3.6 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 69.7 | Aromatic Rings: | 5 |
Heavy Atoms: | 31 | QED Weighted: | 0.74 |
Caco-2 Permeability: | -4.863 | MDCK Permeability: | 0.00004380 |
Pgp-inhibitor: | 0.999 | Pgp-substrate: | 0.193 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.011 |
30% Bioavailability (F30%): | 0.016 |
Blood-Brain-Barrier Penetration (BBB): | 0.339 | Plasma Protein Binding (PPB): | 90.10% |
Volume Distribution (VD): | 0.563 | Fu: | 11.40% |
CYP1A2-inhibitor: | 0.04 | CYP1A2-substrate: | 0.109 |
CYP2C19-inhibitor: | 0.873 | CYP2C19-substrate: | 0.832 |
CYP2C9-inhibitor: | 0.773 | CYP2C9-substrate: | 0.849 |
CYP2D6-inhibitor: | 0.173 | CYP2D6-substrate: | 0.17 |
CYP3A4-inhibitor: | 0.877 | CYP3A4-substrate: | 0.934 |
Clearance (CL): | 1.774 | Half-life (T1/2): | 0.233 |
hERG Blockers: | 0.006 | Human Hepatotoxicity (H-HT): | 0.668 |
Drug-inuced Liver Injury (DILI): | 0.982 | AMES Toxicity: | 0.023 |
Rat Oral Acute Toxicity: | 0.743 | Maximum Recommended Daily Dose: | 0.248 |
Skin Sensitization: | 0.858 | Carcinogencity: | 0.102 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.014 |
Respiratory Toxicity: | 0.74 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003221 | ![]() |
1.000 | D0QL3P | ![]() |
0.346 | ||
ENC002594 | ![]() |
0.701 | D0P3JU | ![]() |
0.321 | ||
ENC006112 | ![]() |
0.536 | D08FTG | ![]() |
0.311 | ||
ENC005251 | ![]() |
0.517 | D09LDR | ![]() |
0.300 | ||
ENC002563 | ![]() |
0.417 | D0U7GK | ![]() |
0.299 | ||
ENC004892 | ![]() |
0.404 | D0T0LM | ![]() |
0.298 | ||
ENC003110 | ![]() |
0.393 | D0E0RY | ![]() |
0.298 | ||
ENC001985 | ![]() |
0.389 | D04QZD | ![]() |
0.296 | ||
ENC004493 | ![]() |
0.373 | D0K4CQ | ![]() |
0.291 | ||
ENC002357 | ![]() |
0.368 | D02NEH | ![]() |
0.286 |